Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance
Authors:
- 1 May 2021
- journal article
- research article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 340, 109448
Abstract
No abstract availableKeywords
Funding Information
- Univerzita Karlova
- Grantová Agentura České Republiky
This publication has 44 references indexed in Scilit:
- Molecular Pharmacokinetics of Catharanthus (Vinca) AlkaloidsThe Journal of Clinical Pharmacology, 2007
- SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5Drug Metabolism and Disposition, 2006
- Cytochrome P450 pharmacogenetics and cancerOncogene, 2006
- Clinical Pharmacokinetics of DocetaxelClinical Pharmacokinetics, 2006
- Cytochrome P450 1B1: A Novel Anticancer Therapeutic TargetFuture Oncology, 2005
- Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8The Journal of Clinical Pharmacology, 2005
- Expression of cytochrome P450 in tumor tissues and its association with cancer developmentFrontiers in Bioscience-Landmark, 2004
- Cytochrome P450 CYP3A4/5 Expression as a Biomarker of Outcome in OsteosarcomaJournal of Clinical Oncology, 2003
- Induction of Cytochrome P4503A by Taxol in Primary Cultures of Human HepatocytesArchives of Biochemistry and Biophysics, 1998
- Clinical Pharmacokinetics of PaclitaxelClinical Pharmacokinetics, 1994